Accessibility Menu

Shin Nippon Biomedical Laboratories(FRA) YB3

Market Cap€308.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A
€7.40
+0.00%
+0.00Today

Shin Nippon Biomedical Laboratories Financials at a Glance

Market Cap

€308.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€188.15

Net Income (TTM)

€29.47

EPS (TTM)

€0.71

P/E Ratio

10.39

Dividend

€0.28

Beta (Volatility)

0.04 (Low)

Price

€7.40

Volume

0

Open

€7.40

Previous Close

€7.40

Daily Range

€7.40 - €7.40

52-Week Range

€5.70 - €10.90

Estimated Earnings Date

N/A

YB3 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Shin Nippon Biomedical Laboratories

Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. Its operations are carried out through the following segments: Preclinical Business, Clinical Business, Translational Research Business, Medipolis Business, and Others. The Preclinical Business segment verifies the efficacy and safety of new drugs using experimental animals and bacterial cells. The Clinical Business segment provides the support services for clinical trials and related statistical, analytical, and consulting services for all aspects of new drug development. The Translational Research Business segment utilizes drug and device development capabilities to accelerate drug development which leads to out-licensing to pharmaceutical companies. The Medipolis Business segment deals with the property management and geothermal power generation businesses. The Others segment engages in the information collection in Europe, which includes real estate and environmental equipment operations. The company was founded in April 1957 and is headquartered in Tokyo, Japan.

Industry

Life Sciences Tools and Services

Employees

1,522

CEO

Ryoichi Nagata, MD, PhD

YB3 Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

13.66%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

9.62%

Dividend Yield

3.77%

Payout Ratio

N/A

Stock Overview

Market Cap

€308.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

41.63M

Volume

0

Avg. Volume

15.152

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Shin Nippon Biomedical Laboratories Performance Analysis

Shin Nippon Biomedical Laboratories annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31EUR 178,061,13930.9%
20242024-03-31EUR 168,926,010-5.1%
20252025-03-31EUR 198,050,53517.2%
20262026-03-31EUR 186,271,638-5.9%
Shin Nippon Biomedical Laboratories annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31EUR 1.03-21.3%
20242024-03-31EUR 0.85-17.9%
20252025-03-31EUR 0.72-14.8%
20262026-03-31EUR 0.63-13.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€42.47

+1.1%

Gross Profit

€21.85

+1.2%

Gross Margin

51.44%

+1.1%

Market Cap

€308.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€0.17

N/A

Employees

1,522

N/A

Net Income

€5.74

+3.7%

EBITDA

€7.08

+2.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€279.41

-1.6%

Total Debt

€202.26

+0.9%

Accounts Receivable

€37.68

+1.1%

Inventory

€92.60

+1.3%

Long Term Debt

€96.94

+0.7%

Short Term Debt

€105.32

+1.5%

Return on Assets

5.57%

+0.9%

Return on Invested Capital

14.41%

+0.9%

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About YB3

What is the current price of Shin Nippon Biomedical Laboratories?

Shin Nippon Biomedical Laboratories is trading at €7.40 per share.

What is the 52-week range for Shin Nippon Biomedical Laboratories?

Over the past 52 weeks, Shin Nippon Biomedical Laboratories has traded between €5.70 and €10.90.

How much debt does Shin Nippon Biomedical Laboratories have?

As of the most recent reporting period, Shin Nippon Biomedical Laboratories reported total debt of €202.26M.

How much cash does Shin Nippon Biomedical Laboratories have on hand?

Shin Nippon Biomedical Laboratories reported €77.14M in cash and cash equivalents in its most recent financial results.

What is Shin Nippon Biomedical Laboratories’s dividend yield?

Shin Nippon Biomedical Laboratories currently has a dividend yield of 3.77%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.